Gallium Pharmaceuticals

Gallium Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel anti-infective therapies that leverage the unique properties of gallium. By exploiting the biological similarity between gallium and iron, the company's lead programs aim to disrupt the metabolism of iron-dependent pathogens, particularly in chronic lung infections. Their primary focus is on treating Pseudomonas aeruginosa and non-tuberculous mycobacteria in patients with cystic fibrosis. The company's approach provides a potential solution to antibiotic resistance by targeting nutritional requirements essential for bacterial survival. Their lead candidate, GAN-101, has demonstrated promising results in Phase 2 clinical trials, showing the potential to improve lung function in patients with persistent infections.